Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update Jan 12, 2022 8:30am EST
Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom Jan 11, 2022 8:30am EST
Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference Jan 10, 2022 9:00am EST
Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update Nov 29, 2021 8:30am EST
Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Sep 08, 2021 8:30am EDT
Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th Aug 11, 2021 7:30am EDT
Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines Aug 04, 2021 8:30am EDT
Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021 Jul 21, 2021 8:30am EDT
Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update Jul 12, 2021 8:30am EDT
